Welcome, Anna Rivkin, our new Chief Business Officer! With over two decades of expertise, Anna brings significant industry experience in establishing strategic alliances, R&D partnerships, in-licensing, and M&A. Learn more about the appointment: https://bit.ly/3Mw03Bp #biotechnology #leadership #innovation #healthcare
Foghorn Therapeutics Inc.
Biotechnology Research
Cambridge, Massachusetts 16,791 followers
About us
Foghorn Therapeutics is pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Our proprietary Gene Traffic Control® platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing us to identify, validate and potentially drug targets within the system.
- Website
-
http://www.foghorntx.com
External link for Foghorn Therapeutics Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
- Founded
- 2016
Locations
-
Primary
500 Technology Sq
Suite 700
Cambridge, Massachusetts 02139, US
Employees at Foghorn Therapeutics Inc.
Updates
-
We're looking forward to participating at the 2024 Wells Fargo Conference and presenting at the Morgan Stanley 22nd Annual Global Healthcare Conference. Learn more about our participation and register for the webcast at Morgan Stanley to hear Foghorn CEO Adrian Gottschalk discuss our approach to modulating the chromatin regulatory system, advances made across our pipeline, and upcoming milestones: https://bit.ly/3MlSM6W #investors #biotechnology #oncology
-
-
Our team at Foghorn is united by our mission to transform the lives of people across a wide spectrum of diseases. Lisa Hawver shares what she enjoys about our community. Learn more about our culture: https://lnkd.in/g8_dkf-j #biotechcareers #innovation
-
-
Attending the American Chemical Society Fall 2024 conference? Melek Nihan Ucisik, Principal Scientist at Foghorn, will give a presentation about the design of targeted protein degraders, highlighting an example with BRD9, an established oncology target. Danette Daniels, Head of our Protein Degrader Platform, will discuss recent advancements in our preclinical Selective CBP Degrader program, which is on track for IND-enabling studies by the end of this year. Learn more and be sure to catch our talks: https://bit.ly/3WPqFCh #biotechnology #innovation #oncology
-
-
Today, we provided our second quarter 2024 financial and corporate update. Read the announcement to learn about our recent highlights and upcoming milestones for FHD-286 in relapsed and/or refractory acute myeloid leukemia (R/R AML), FHD-909 in SMARCA4 mutated non-small cell lung cancer (NSCLC), and for our selective CBP degrader program: https://bit.ly/3WTp9A9 #biotechnology #investors #healthcare
-
-
Our team enjoyed some well-deserved sunshine and great food at our FogFest Summer BBQ earlier this month. It was a fun day filled with laughter, games, and great conversations. Thanks to everyone at Foghorn for making our journey to transform the lives of patients so special, in and out of the office!
-
-
We're pleased to share new research in collaboration with NEO Proteomics that was published in ACS Publications. In addition to mapping the binding site of a crotonylated histone 3 peptide (H3K14Cr) to BAF45D, this study went on to demonstrate the direct binding of H3K14Cr to BRM. Overall, this study illustrates the power of mass spectrometry-based protein footprinting to map binding interfaces in large, multisubunit complexes with new insights into the BRG-/BRM-associated factor (BAF) chromatin remodeling complex. Read here: https://bit.ly/3xHHer0
-
-
Have you read the Q&A with Foghorn’s scientific co-founder, Cigall Kadoch, in Nature Portfolio? She and Asher Mullard discuss her experience with chromatin remodeling complexes, why this is an exciting time for the field, and highlight Foghorn’s precision therapeutic candidates targeting the chromatin regulatory system. Nature subscribers can read the full article here: https://lnkd.in/gUFT2d_R #biotechnology #innovation #cancerresearch
-
Thanks to the Federation of American Societies for Experimental Biology (FASEB) for having us at the Ubiquitin and Ub-like Proteins conference! Head of our protein degrader platform, Danette Daniels, shared our innovative work to modulate the chromatin system with therapeutic protein degraders. #UBPSRC #drugdevelopment
-
-
This week, we’re joining the scientific community for a special conference from the American Association for Cancer Research on expanding and translating cancer synthetic vulnerabilities. See the program and be sure to catch our presentations: https://bit.ly/45f6CAR #drugdevelopment #oncology
-